AVX420 and FOL026 have demonstrated their therapeutic potential for the treatment of fibrosis, e.g., in chronic kidney disease or liver disease. The project is currently in the early preclinical phase with plans to test AVX420 and FOL026 in kidney and liver fibrosis disease models. The aim is to begin Phase I trials at the end of 2023 or early 2024.
Coegin Pharma’s research team, led by Professor Berit Johansen at The Norwegian University of Science and Technology (NTNU), plays a key role in the development of leukaemia and fibrosis projects. The team has internationally recognised competencies in cPLA2a and solid experience in fibrosis, through collaboration with Harvard Medical School.